Bioprocess Analyzers Global Market Report 2024

The bioprocess analyzers market size has grown rapidly in recent years. It will grow from $1.8 billion in 2023 to $1.99 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. Expansion observed in the historical period can be attributed to several key factors. The increasing demand for personalized medicine drove growth in the bioprocessing industry, as personalized treatments often require more complex bioprocesses to manufacture customized medications tailored to individual patients. Additionally, advancements in biotechnology and genetic engineering led to the development of more complex bioprocesses to produce novel biopharmaceuticals and therapies. These factors combined to fuel the growth of the bioprocessing industry during the historic period.

The bioprocess analyzers market size is expected to see rapid growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. Anticipated growth in the forecast period can be attributed to several key drivers. The rise of biosimilar and bio-better products is expected to drive demand for bioprocessing technologies and services, as companies seek to develop and manufacture these innovative therapies. Additionally, the expansion of bioprocessing industries, fueled by increasing demand for biopharmaceuticals and biotechnology products, will contribute to growth in the sector. Increased investment in research and development will also drive advancements in bioprocessing technology and innovation, further stimulating growth.

The surge in demand for biopharmaceuticals is poised to drive substantial growth in the bioprocess analyzer market. Biopharmaceuticals, derived from biological sources, are witnessing increased demand due to innovative research and development endeavors leading to the creation of novel biologics and biosimilars. Bioprocess analyzers play a critical role in monitoring various parameters during biopharmaceutical production, including cell growth, protein expression, and product purity. For example, data from January 2024, as per IQVIA, forecasts global biotech spending to surpass $892 billion by 2028, indicating significant growth opportunities in the biopharmaceutical industry. Moreover, according to the National Library of Medicine in April 2022, pharmaceutical spending in the United States surged by 7.7% in 2021 compared to the previous year, reaching a total of $576.9 billion, further highlighting the increasing demand for biopharmaceuticals and consequently, the growth of the bioprocess analyzer systems market.

Key players in the bioprocess analyzer market are focusing on developing advanced solutions such as optical in-line analyzers to maintain a competitive edge. Optical in-line analyzers utilize optical technology to provide real-time monitoring and analysis of critical parameters in bioprocessing applications. For instance, 908 Devices Inc. launched MAVERICK in September 2023, an advanced optical in-line analyzer offering real-time monitoring and control of essential factors such as glucose, lactate, and total biomass in mammalian cell cultures. The device's comprehensive process fingerprint data enables biopharmaceutical experts to optimize large-scale bioprocesses efficiently, accelerating the development of cell culture media and feeding and control plans. MAVERICK, utilizing Raman spectroscopy, measures vital process parameters in real-time, enhancing process comprehension, performance optimization, and batch-to-batch reproducibility in cell culture automation for biologic production.

In September 2022, in a strategic move to strengthen its bioanalytics platform, 908 Devices acquired TRACE Analytics for $15.3 million. This acquisition bolsters 908 Devices' capabilities in bioprocess analysis, enabling the development of a connected and comprehensive bioanalytics platform. TRACE Analytics, a manufacturer of bioprocess analyzers and supplier of online analytical technologies, brings valuable expertise and technologies to enhance 908 Devices' bioanalytics offerings, further solidifying its position in the bioprocess analyzer market.

Major companies operating in the bioprocess analyzers market are Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Thermo Fisher Scientific, MilliporeSigma, Sartorius AG, Beckman Coulter Inc., Waters Corporation, Bio-Rad Laboratories, Bruker Corporation, Agilent Technologies, GE Healthcare, Pall Corporation, Eppendorf AG, HORIBA Ltd., Promega Corporation, Nova Biomedical, Hamilton Company, Macherey-Nagel GmbH & Co. KG, BioTek Instruments, Zymo Research Corporation, Gilson Inc., Metrohm AG, Biochrom Ltd., PerkinElmer Inc.

North America was the largest region in the bioprocess analyzers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess analyzers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bioprocess analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bioprocess analyzers are analytical devices or systems specifically engineered to monitor, analyze, and control various factors and procedures involved in the manufacturing of biopharmaceuticals, bioprocessing, and biotechnology. These analyzers play a critical role across various sectors by ensuring the efficacy and quality of bioprocessing activities. They enable real-time monitoring and control of critical parameters, thereby facilitating the optimization of bioprocesses and ensuring compliance with regulatory standards.

The primary types of bioprocess analyzer products encompass instruments and consumables. Instruments are essential tools utilized in bioprocessing, enabling precise measurement, analysis, control, and optimization of bioprocesses to attain desired outcomes in terms of product yield, quality, and efficiency. These instruments find applications in various sectors such as antibiotics, recombinant proteins, biosimilars, and others. They are utilized by diverse end-users including biopharmaceutical companies, contract manufacturing organizations, contract research organizations, and others involved in bioprocessing activities.

The bioprocess analyzers market research report is one of a series of new reports that provides bioprocess analyzers market statistics, including bioprocess analyzers industry global market size, regional shares, competitors with a bioprocess analyzers market share, detailed bioprocess analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocess analyzers industry. This bioprocess analyzers market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bioprocess analyzers market consists of sales of biosensors, spectroscopic sensors, spectrophotometers, and biochemical analyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.